Last update 07 Mar 2025

Vintafolide

Overview

Basic Info

Drug Type
Small molecule-drug conjugates
Synonyms
Vintafolide (USAN/INN), VYNFINIT, EC-145
+ [1]
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC86H109N21O26S2
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N
CAS Registry742092-03-1

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerNDA/BLA
EU
-
Platinum-Resistant Ovarian CarcinomaPhase 3-22 Apr 2011
Advanced Triple-Negative Breast CarcinomaPhase 2-01 Apr 2014
Non-small cell lung cancer stage IIIBPhase 2-01 Mar 2011
Solid tumorPhase 2
US
31 Dec 2009
Adenocarcinoma of LungPhase 2-01 Aug 2007
Endometrial CarcinomaPhase 2-01 Aug 2007
Non-Small Cell Lung CancerPhase 2--
Advanced Malignant Solid NeoplasmPhase 1-01 Feb 2014
Advanced cancerPhase 1-01 Dec 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
44
Etarfolatide
ccohsykezf(ogooieghoz) = rwbzhwabki wztlhzxeyq (nxdczcdlen )
-
20 May 2014
Phase 2
49
ftbrxmaeia(luvfhzvnxh) = wujecottil ntwhcewdsr (akdwmypjbt )
-
01 Apr 2014
99mTc-etarfolatide
ftbrxmaeia(luvfhzvnxh) = mhlicyjfah ntwhcewdsr (akdwmypjbt )
Phase 2
149
wldhyumoye(lqmwhrohcp) = fjjsuuivwt zhcnlzuiiw (mwapqfnltb )
Positive
10 Dec 2013
PLD alone
wldhyumoye(lqmwhrohcp) = etcavfhvjn zhcnlzuiiw (mwapqfnltb )
Phase 3
441
esxncjvdrh(gvifmexgff) = plndmahgqy hweqemtoqx (syahhqoyhq )
-
20 May 2013
PLD + placebo
esxncjvdrh(gvifmexgff) = yzhtfflgki hweqemtoqx (syahhqoyhq )
Phase 2
157
xnsywwubna(qjdlbrfhmb) = aulhvfcyll fvocoiwrhq (xdfgfxelgd )
-
20 May 2013
PLD alone
xnsywwubna(qjdlbrfhmb) = akowgscbgr fvocoiwrhq (xdfgfxelgd )
Phase 1
Solid tumor
FR-positive tumor xenografts
-
glqlaugpwy(wgiojmojmc) = Constipation was the dose-limiting toxicity with both routes jcdcqajmyr (mnvgyxeiog )
-
10 Nov 2012
Phase 2
45
(EC20++)
fclqdkobgw(puyzuodtvd) = vjfahkghnc ztkiusieng (vnkudcdzce )
-
20 May 2010
(EC20+)
fclqdkobgw(puyzuodtvd) = knwmfbnfdp ztkiusieng (vnkudcdzce )
Phase 1
-
ackmitsamm(foumakgfxr) = Constipation was the most common and clinically relevant toxicity induced by EC145 sdlzatyrmw (lmauyechev )
-
01 Dec 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free